Tasigna nilotinib regulatory update

FDA accepted for filing and granted Priority Review to an NDA from Novartis for Tasigna nilotinib for first-line treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) ...